<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03116113</url>
  </required_header>
  <id_info>
    <org_study_id>NSR-RPGR-01</org_study_id>
    <nct_id>NCT03116113</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa</brief_title>
  <acronym>XIRIUS</acronym>
  <official_title>A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NightstaRx Ltd, a Biogen Company</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NightstaRx Ltd, a Biogen Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical trial of AAV8-RPGR retinal gene therapy for patients with X-linked retinitis
      pigmentosa
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2/3, first-in-human, multi-centre, dose-escalation interventional study of
      AAV8-RPGR in male subjects with genetically confirmed XLRP. Part I is a dose-selection study;
      Part II is a dose-expansion study, comparing 2 doses, and a third untreated group to allow
      for a controlled comparison of efficacy and safety.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Part I unmasked,Part II masked. Outcomes assessor masked to treatment; subject, surgeon, investigator/site team, and sponsor masked to dose.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part I: Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of patients with a DLT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part I: Incidence of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of patients with a TEAE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: Improvement from Baseline in microperimetry</measure>
    <time_frame>12 Months</time_frame>
    <description>Proportion of patients with improved microperimetry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: The safety endpoint is incidence of TEAEs over a 12-month period</measure>
    <time_frame>12 Months</time_frame>
    <description>Proportion of patients with a TEAE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity (BCVA)</measure>
    <time_frame>24 Months (Part I),12 Months (Part II)</time_frame>
    <description>ETDRS visual acuity chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microperimetry</measure>
    <time_frame>24 Months (Part I),12 Months (Part II)</time_frame>
    <description>Change in sensitivity (dB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spectral domain optical coherence tomography (SD-OCT)</measure>
    <time_frame>24 Months (Part I)</time_frame>
    <description>Ellipsoid Zone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fundus autofluorescence (AF)</measure>
    <time_frame>24 Months (Part I)</time_frame>
    <description>To assess changes in the retina from baseline in autofluorescence imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Fields</measure>
    <time_frame>12 Months (Part II)</time_frame>
    <description>Octopus 900 pro will be used to assess changes in central peripheral vison from baseline</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>X-Linked Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Part I: Dose 1 AAV8-RPGR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, subretinal administration of dose 1 as a single dose AAV8-RPGR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I: Dose 2 AAV8-RPGR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, subretinal administration of dose 2 as a single dose AAV8-RPGR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I: Dose 3 AAV8-RPGR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, subretinal administration of dose 3 as a single dose AAV8-RPGR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I: Dose 4 AAV8-RPGR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, subretinal administration of dose 4 as a single dose AAV8-RPGR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I: Dose 5 AAV8-RPGR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, subretinal administration of dose 5 as a single dose AAV8-RPGR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I: Dose 6 AAV8-RPGR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, subretinal administration of dose 6 as a single dose AAV8-RPGR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: High dose AAV8-RPGR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, subretinal administration of high dose AAV8-RPGR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: Low dose AAV8-RPGR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, subretinal administration of Low dose AAV8-RPGR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: Untreated Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Untreated group to allow for a controlled comparison of efficacy and safety</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AAV8-RPGR</intervention_name>
    <description>Comparison of different dosages of AAV8-RPGR</description>
    <arm_group_label>Part I: Dose 1 AAV8-RPGR</arm_group_label>
    <arm_group_label>Part I: Dose 2 AAV8-RPGR</arm_group_label>
    <arm_group_label>Part I: Dose 3 AAV8-RPGR</arm_group_label>
    <arm_group_label>Part I: Dose 4 AAV8-RPGR</arm_group_label>
    <arm_group_label>Part I: Dose 5 AAV8-RPGR</arm_group_label>
    <arm_group_label>Part I: Dose 6 AAV8-RPGR</arm_group_label>
    <arm_group_label>Part II: High dose AAV8-RPGR</arm_group_label>
    <arm_group_label>Part II: Low dose AAV8-RPGR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion Criteria:

          -  Male

          -  Part I: &gt;= 18 years

          -  Part II: &gt;= 10 years

          -  Documentation of a pathogenic mutation in the RPGR gene

        Key exclusion Criteria:

          -  Participated in a gene therapy trial previously or a clinical trial with an
             investigational drug in the past 12 weeks
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>NightstaRx Ltd, a Biogen Company</last_name>
    <phone>+1 866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 29, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>XLRP</keyword>
  <keyword>Ophthalmology</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Retinitis Pigmentosa GTPase Regulator (RPGR)</keyword>
  <keyword>AAV8</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

